Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norovirus GII.4 Challenge Dose Finding
NCT04174560Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2022
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Phase 1, double-blind trial (3 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Occurrence of Norovirus-associated Illness. Started Mar 2022; status: completed.
Beyond the preview
Go deeper on NCT04174560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04174560.